Skip to main content

Challenging the gaps in global cancer concepts by a real life tumor: human childhood neuroblastoma

Objective

The successes of cancer research stem from the identification of oncogenes and tumour suppressor genes and the study of their pathways in animal and cell line models. Confronting these models with ‘real life’ human cancer has often been a challenge. This grant aims at integral understanding of the aggressive childhood tumor neuroblastoma. Starting point is a huge database for this tumor. We established mRNA, miRNA, CGH and SNP profiles for a series of neuroblastoma, and sequenced their whole genomes. Over 1500 mRNA profiles of cell lines with manipulated gene expression complete this resource. A novel bioinformatic platform integrated all molecular and clinical data. Several research topics have emerged: (1) Recurrent mutations were detected in neuronal growth cone genes. We will investigate whether failed neuritogenesis is oncogenic; (2) Contrary to the paradigm that cancer is caused by gene mutations, our data suggest that human tumours equally much result from chromosomal gains and losses. They proportionally change the expression of hundreds of otherwise intact genes. We will investigate how copy number changes activate oncogenic pathways. (3) Each neuroblastoma includes two cell types, which at low frequency convert into each other. They differ in mesenchymal and neuro-epithelial character, cancer pathway activation, motility and drug sensitivity and thereby are at the crossroads of cancer stem cell-, drug resistance- and metastasis-research. Transgene expression could induce transitions between both cell types in vitro, which will allow us to elucidate the wiring of both states. (4) Neuroblastoma can go in remission upon treatment, but often relapse as fatal therapy resistant tumour. This plasticity may stem from resistant mesenchymal cells, inter-conversion of cell types and continued chromosomal copy number changes. We will target pathways essential to each cell type to contain plasticity and identify therapeutic options to prepare for clinical testing.

Field of science

  • /medical and health sciences/basic medicine/pharmacology and pharmacy/drug resistance
  • /medical and health sciences/medical biotechnology/cells technologies/stem cells
  • /natural sciences/biological sciences/genetics and heredity/mutation
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /natural sciences/biological sciences/genetics and heredity/genome

Call for proposal

ERC-2013-ADG
See other projects for this call

Funding Scheme

ERC-AG - ERC Advanced Grant

Host institution

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Address
Meibergdreef 15
1105AZ Amsterdam
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 2 499 802,80
Principal investigator
Rogier Versteeg (Prof.)
Administrative Contact
Hasnae Bouhbouh (Mrs.)

Beneficiaries (1)

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Netherlands
EU contribution
€ 2 499 802,80
Address
Meibergdreef 15
1105AZ Amsterdam
Activity type
Higher or Secondary Education Establishments
Principal investigator
Rogier Versteeg (Prof.)
Administrative Contact
Hasnae Bouhbouh (Mrs.)